Trial Profile
A Phase II Two Cohort Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms Tricotel
- Sponsors Roche
- 21 Oct 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 14 Jul 2023 According to Results published in the Lancet Oncology, BRAFV600 wild-type cohort was closed early after enrolment of 15 patients and because of early closure of this cohort, the primary endpoint of intracranial objective response rate by IRC assessment was not done in this cohort.
- 14 Jul 2023 Results published in the Lancet Oncology